Core Viewpoint - Shanghai Baoxin Software Co., Ltd. announced the repurchase and cancellation of part of its restricted stock due to unmet performance targets for 2024 and changes in the status of certain incentive recipients [1][3]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase of restricted stock is due to the failure to meet the 2024 performance assessment targets, as well as the retirement and departure of some incentive recipients [1][3]. Details of the Repurchase - The company will repurchase a total of 13,025,056 shares at a price of 14.1875 yuan per share, affecting 898 incentive recipients [2][3]. - The repurchase includes 12,813,345 shares related to the unmet performance targets for the 2024 assessment year [3]. Changes in Incentive Recipients - Eight incentive recipients have retired, and several others have left the company or been reassigned, necessitating the repurchase of their unvested restricted stock [3][4]. Completion and Legal Compliance - The repurchase will be completed by August 22, 2025, and the company has initiated the necessary legal and procedural steps to ensure compliance with regulations [4][5]. - A legal opinion confirms that the repurchase complies with all relevant laws and the company's incentive plan [5].

证券代码:600019 证券简称：宝钢股份 公告编号：临 2025-039 宝山钢铁股份有限公司 关于第三期限制性股票计划限制性股票 回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 回购注销原因：因公司 2024 年业绩考核目标未达成，宝山钢 铁股份有限公司（以下简称"宝钢股份"、"公司"）回购注销 第三期 A 股限制性股票计划激励对象已授予未解锁的限制性股 票。 ? 本次注销股份的有关情况 回购股份数量 注销股份数量 注销日期 一、本次限制性股票回购注销的决策与信息披露 公司于 2025 年 4 月 25 日召开宝钢股份第八届董事会第五十二次 会议，审议通过《关于第三期限制性股票计划回购注销有关事宜的议 案》，同意公司按照授予价格 4.29 元/股，回购因公司 2024 年业绩考 核目标未达成的 1,762 名激励对象持有的尚未达到解除限售条件的限 制性股票共 126,559,250 股，并同意将该议案提交股东大会审议。公司 于 2025 年 5 月 20 日召开宝钢股份 2024 年度 ...

Group 1: Company Overview - The company operates multiple retail sub-brands, covering 11 cities in Zhejiang Province with over 200 stores, including DTP pharmacies with more than 500 product specifications [1] Group 2: Financial Performance - The company’s cash distribution for 2024 is planned at 200 million CNY, representing 38.06% of the net profit attributable to shareholders [2] - Cumulative cash dividends over the last three accounting years (2022-2024) amount to 423 million CNY, which is 103.39% of the average net profit during this period [2] Group 3: Strategic Acquisitions - The company acquired 100% of Huadong Pharmaceutical for 369.1 million CNY, enhancing its market share and bargaining power in the Zhejiang market [1] Group 4: Risk Management - The company has established a comprehensive credit risk management system to monitor accounts receivable turnover across different regions and customer types [1] Group 5: Employee Incentives - The company has implemented a restricted stock plan for key employees in 2021 and 2022, with performance indicators including net profit growth and return on equity [2]